Core Insights - The appointment of Drs. Philip C. Amrein and Alex Kentsis to the Scientific Advisory Board (SAB) enhances the strategic guidance for SELLAS Life Sciences as it approaches significant milestones in its therapeutic pipeline [1][2] - The company is expecting full topline Phase 2 data for SLS009 in acute myeloid leukemia (AML) and the final analysis of the Phase 3 REGAL trial of GPS in AML within the year [2] Company Overview - SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [5] - The lead product candidate, GPS, targets the WT1 protein found in multiple tumor types and has potential as both a monotherapy and in combination with other therapies [5] - SLS009 (tambiciclib) is a differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to existing CDK9 inhibitors, showing a high response rate in AML patients with unfavorable prognostic factors [5] New Advisory Board Members - Dr. Philip C. Amrein is an Assistant Professor of Medicine at Harvard Medical School, specializing in leukemia and leading numerous clinical trials [3] - Dr. Alex Kentsis is the founding Director of the MSK Tow Center for Developmental Oncology and focuses on improving understanding of blood and solid tumors, particularly in pediatric oncology [4]

- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical eff ...